Biotech stocks surge as drug innovation and dealmaking gather pace

The iShares Biotech ETF has gained 24% through October 2026, helped by clinical results, acquisitions and new technology. The rally follows a long slump after the Covid era and a year of rising deal activity.

What happened

Biotech stocks have surged. Drivers include strong clinical trial results, acquisition activity, and advances in mRNA, genomics and AI-driven drug discovery [1]. The iShares Biotech ETF has gained 24% through October 2026, and Moderna is up 587% year-to-date [1].

Several catalysts stand behind the move. About 66 novel drugs are with the FDA, and biopharma dealmaking reached $134 billion in the first half of 2026 [1]. AI in drug discovery is projected to grow from $20B in 2025 to $160B in 2035 [1]. The sector is also recovering from a fallow period that followed the Covid-era downturn [1].

How we got here

The current rally builds on a year of shifting fortunes in drug development. On 11 December 2025, Zealand Pharma set out its five-year 'Metabolic Frontier 2030' strategy, which targets five drug launches in a market projected at $150 billion annually by 2030 [2]. At that point valuations in obesity treatment had separated sharply [2]. Zealand was down 29% year-to-date and Novo Nordisk down 50%, while Eli Lilly's more potent portfolio had outperformed [2]. The market was moving away from a two-player, winner-take-most structure toward several competitors [2].

On 30 January 2026, commentary ahead of earnings pointed to GLP-1 trial updates as a focus for Lilly's results that week [3]. Broader equities were also in motion. By 3 June 2026 the S&P 500 had rallied nearly 20% over nine weeks [4].

The deal picture then firmed. On 4 June 2026, PitchBook data showed $106 billion across 201 global biopharma deals year-to-date [5]. That put the sector on pace to exceed $250 billion and possibly make 2026 the strongest year since the 2019 pre-pandemic peak [5]. Activity was dominated by strategic bolt-on acquisitions of $1 billion to $5 billion rather than mega-mergers [5]. Patent cliffs, buoyant public markets and Big Pharma's need to replenish its drug portfolios in oncology, metabolic disease and central nervous system areas, including Alzheimer's, were cited as drivers [5]. Executives described sustained appetite for near-commercial assets and earlier-stage technology despite a deteriorating interest-rate environment [5]. Western pharma also kept sourcing innovation from China, even though draft U.S. rules limit use of Chinese clinical data [5].

What changed by late October is that strong dealmaking had been joined by sector-wide equity gains, with the iShares Biotech ETF up 24% and first-half dealmaking put at $134 billion [1]. That compares with the $106 billion year-to-date figure reported in early June [5].

Other recent items show innovation spreading beyond the large U.S. names. On 1 October 2026, lenacapavir, Gilead's twice-yearly injectable HIV prevention drug, was described as a breakthrough [6]. It showed zero HIV infections in a 2024 trial of more than 2,000 young women in South Africa and Uganda, and the WHO recommends it [6]. Access remains contested [6]. Global HIV funding fell 18% in 2025, and at least 26 middle-income countries are excluded from Gilead's generic licensing [6]. Royalty-free generics are expected around 2027 at roughly $40 per person annually, versus about $28,000 in the US [6].

On 15 October 2026, Brazil's clinical-research law was credited with lifting the country's global clinical-trial ranking from 18th to 12th place between 2025 and the first half of 2026, according to Interfarma [7]. Industry spend is projected above R$2 billion annually [7].

Why it matters for markets

The rally could reflect a broader repricing of drug-development risk. If clinical results keep arriving and the roughly 66 novel drugs with the FDA advance, the sector's recovery from the post-Covid slump could continue [1].

Acquisition activity could also support valuations of smaller developers. Large drugmakers facing patent cliffs need to replenish their portfolios, and bolt-on deals of $1 billion to $5 billion could keep turning that need into demand for targets [5]. A deal pace above $250 billion for the full year would mark the strongest year since 2019 [5].

The AI-driven drug discovery projection suggests a possible technology channel. The growth from $20B to $160B is a forecast, not an outcome [1].

There are also constraints. The gains look concentrated in some names, such as Moderna's 587% rise, so the ETF's 24% advance could mask wide dispersion [1]. The obesity market shows that strong sector themes can coexist with sharp declines for individual companies, as Novo Nordisk was down 50% as competition intensified [2]. Executives acknowledged a deteriorating interest-rate environment, yet deal appetite has persisted [5]. Pricing and access disputes, as in the lenacapavir case, could affect how revenue from new drugs develops outside wealthy markets [6]. No direct market channel from Brazil's trial-activity data to listed biotech valuations is apparent.

What to watch

• Whether deal volumes keep pace with the more than $250 billion annual run rate projected in June, and whether deals stay in the $1 billion to $5 billion range [5].
• Further clinical trial readouts and FDA decisions on the roughly 66 novel drugs [1].
• Whether the 24% ETF gain broadens beyond a few outsized performers [1].
• Competition in obesity treatment, including Zealand Pharma's plan for five launches and the market's move toward several competitors [2].
• Final U.S. rules on the use of Chinese clinical data, which are currently in draft form [5].
• Generic HIV prevention supply expected around 2027, and whether licensing coverage widens beyond the countries now excluded [6].
• Whether Brazil's shorter review timelines translate into industry spend above R$2 billion annually [7].

Sources

1. US Top News and Analysis: Biotech stocks are surging. How investors can play the new drug innovation boom, 24 Oct 2026
2. US Top News and Analysis: Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly, 11 Dec 2025
3. US Top News and Analysis: Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data, 30 Jan 2026
4. US Top News and Analysis: Historic stock rally faces key test, 03 Jun 2026
5. US Top News and Analysis: ‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid, 04 Jun 2026
6. Al Jazeera: HIV prevention drug hailed as breakthrough, but who gets access?, 01 Oct 2026
7. Feed Últimas: Participação do Brasil em pesquisas clínicas cresce após marco legal, 15 Oct 2026

---

FinUties generates this briefing for transparency. Published after editorial review. It may summarize source data and does not provide investment recommendations. Data availability at one timestamp does not guarantee future continuity.

Provenance

• Study: event-desk-20261026-biotech-stocks-surge-as-drug-innovation-and-dealmaking-gathe (271db974-cd7d-499b-a20d-11baff6a8515)
• Author: FinUties Research
• Approved by: FinUties Research at 2026-10-26T12:59:24.257037Z
• Kind: event brief (news sources, not a FinUties dataset study)
• Cited sources: 7 from 3 outlets, all licensed for public use

• Earlier related events cited from 2025-12-11

• Manifest: /api/v1/research/studies/event-desk-20261026-biotech-stocks-surge-as-drug-innovation-and-dealmaking-gathe/manifest

• Replay tolerance: append_only_sources